Evolocumab
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Atherosclerotic Cardiovascular Disease
Conditions
Atherosclerotic Cardiovascular Disease
Trial Timeline
Oct 3, 2017 → Nov 2, 2020
NCT ID
NCT03096288About Evolocumab
Evolocumab is a approved stage product being developed by Amgen for Atherosclerotic Cardiovascular Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03096288. Target conditions include Atherosclerotic Cardiovascular Disease.
What happened to similar drugs?
7 of 20 similar drugs in Atherosclerotic Cardiovascular Disease were approved
Approved (7) Terminated (0) Active (13)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (17)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06140095 | Phase 1 | UNKNOWN |
| NCT04539223 | Approved | UNKNOWN |
| NCT03944577 | Phase 2 | Completed |
| NCT03331666 | Approved | Terminated |
| NCT03403374 | Approved | Completed |
| NCT03096288 | Approved | Completed |
| NCT03080935 | Phase 3 | Terminated |
| NCT02957604 | Pre-clinical | Terminated |
| NCT02624869 | Phase 3 | Completed |
| NCT02867813 | Phase 3 | Completed |
| NCT02585895 | Phase 3 | Completed |
| NCT02304484 | Phase 3 | Completed |
| NCT02275156 | Phase 1 | Completed |
| NCT01652703 | Phase 2 | Completed |
| NCT01624142 | Phase 2/3 | Completed |
| NCT01439880 | Phase 2 | Completed |
| NCT01380730 | Phase 2 | Completed |
Competing Products
20 competing products in Atherosclerotic Cardiovascular Disease